Poland· PL-100469394
Prothromplex Total NF
A coagulation factor ix, ii, vii and x in combination product containing prothrombinum multiplex humanum, registered in Poland by Takeda Pharma Sp. z o.o.. The same ATC class is registered in 11 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Coagulation factor ix, ii, vii and x in combination is registered in 11 of 19 countries.
Countries holding a registration under ATC B02BD01 (coagulation factor ix, ii, vii and x in combination), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Coagulation factor ix, ii, vii and x in combination · ATC B02BD01
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
URPL (Poland)- Active substance
- Prothrombinum multiplex humanum
- Manufacturer
- Takeda Pharma Sp. z o.o.
- Country
- Poland (PL)
- ATC code
- B02BD01
- ATC class
- Coagulation factor IX, II, VII and X in combination
- Defined daily dose
- 1.6 TSD, E
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin07038319160972
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
3 interactions on record for coagulation factor ix, ii, vii and x in combination.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Coagulation factor ix, ii, vii and x in combination · interactions on record
3 records
- 2 severe
- 1 moderate
Most severe, free to view
- CarfilzomibL01XG02severe
- CarfilzomibL01XX45severe
- PegvaliaseA16AB19moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Coagulation factor ix, ii, vii and x in combination in 1 other country
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/6d1b0ec8-03a5-45fc-98fc-e7d3081a7047 GET /v1/drugs/6d1b0ec8-03a5-45fc-98fc-e7d3081a7047?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Proszek i rozpuszczalnik do sporządzania roztworu do wstrzykiwań",
"source": "urpl",
"strength": "500 j.m.",
"packaging": "07038319160972 ¦ Rp ¦ 151055\n1 fiol. 500 j.m. proszku ¦ 1 fiol. 17 ml rozp. ¦ 1 system do rekonstytucji Mix2Vial",
"substance": "Prothrombinum multiplex humanum 500 j.m.",
"common_name": "Prothrombinum multiplex humanum",
"pl_product_id": "100469394",
"pozwolenie_nr": "27744",
"auth_procedure": "DCP",
"authorisation_validity": "2028-08-23"
}See everything about coagulation factor ix, ii, vii and x in combination.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.